BeyondSpring announced a leadership transition effective July 1, 2026, appointing Min Qiu as CEO and Na Li as CFO to drive execution of the confirmatory Phase 3 DUBLIN-4 trial for Plinabulin, a cancer drug targeting non-small cell lung cancer. The changes aim to sharpen focus on completing this key trial, which builds on positive Phase 3 results showing improved survival and reduced side effects. The company also highlighted Plinabulin's strong scientific foundation and long patent protection through 2036, with potential extension to 2041. This leadership shift is designed to accelerate development, expand Plinabulin’s clinical applications, and strengthen global partnerships and investor relations, particularly in Asia.
Taiwan Semiconductor Manufacturing Company (TSMC) reported a 23.4% increase in second-quarter profit from the previous quarter, surpassing analyst estimates. The company's net income reached NT$706.56 billion ($39.45 billion), a record high for the f...
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
